Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 1998, p. 1133-1138, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
CNI-H0294, a Nuclear Importation Inhibitor of the
Human Immunodeficiency Virus Type 1 Genome, Abrogates Virus Replication
in Infected Activated Peripheral Blood Mononuclear Cells
Omar K.
Haffar,1,*
Molly
D.
Smithgall,1
Serguei
Popov,2
Peter
Ulrich,2
A. Gregory
Bruce,1
Steven G.
Nadler,1
Anthony
Cerami,2 and
Michael I.
Bukrinsky2
Bristol-Myers Squibb Pharmaceutical Research
Institute, Seattle, Washington 98121,1 and
The Picower Institute for Medical Research, Manhasset, New York
110302
Received 26 September 1997/Returned for modification 18 December
1997/Accepted 9 February 1998
 |
ABSTRACT |
Active nuclear importation of the human immunodeficiency virus
(HIV) type 1 (HIV-1) preintegration complex (PIC) is required for the
productive infection of nondividing cells, but it is believed to be
dispensable for the infection of proliferating cells, such as activated
T lymphocytes. To investigate this question, we exploited the
properties of the small arylene bis (methyl ketone) compound CNI-H0294.
We have previously shown that this compound associated with the HIV-1
matrix protein nuclear localization sequence and blocked binding of the
HIV-1 PIC to yeast karyopherin
. CNI-H0294 abrogated nuclear
importation of the HIV-1 genome in macrophages and effectively
inhibited infection of nondividing cells. In this study we demonstrate
that CNI-H0294 inhibits binding of the HIV-1 PIC to human karyopherin
and reduces nuclear importation of the viral genome in primary
peripheral blood mononuclear cells (PBMCs). We also demonstrate that
CNI-H0294 inhibits acute infection of PBMC cultures in vitro with a
primary isolate of HIV-1 and reduces virus replication and virus load
in cultures of endogenously infected PBMCs from seropositive
individuals. Thus, as for infection of nondividing, terminally
differentiated macrophages, HIV-1 uses active nuclear importation of
the virus genome to infect activated CD4+ T cells. These
results support nuclear importation as a novel target and CNI-H0294 and
its derivatives as novel compounds for therapeutic intervention in HIV
infection and AIDS.
 |
INTRODUCTION |
Human immunodeficiency virus (HIV)
type 1 (HIV-1) and other lentiviruses infect nondividing, terminally
differentiated cells such as primary macrophages (17, 18),
primary blood dendritic cells (27), and epidermal
Langerhans' cells (43). This is primarily due to the active
importation of the HIV-1 preintegration complex, which incorporates the
viral genome, across the intact nuclear envelope of the nondividing
cell (5, 6, 50). This active process obviates the
requirement for cell division, thus allowing HIV-1 to infect
nonproliferating as well as proliferating cells (28, 29,
50), the usual targets of retroviruses (29, 44).
It was recently shown (16, 41) that the preintegration
complex (PIC) of HIV-1 associates with karyopherins, the cellular proteins involved in active nuclear import (for a review, see reference
37). Karyopherin
binds to target proteins via
their nuclear localization sequence (NLS), while karyopherin
mediates docking of the karyopherin
-target protein complex to
nuclear pore structures (1, 19, 20, 25, 35, 42). Two forms of karyopherin
have been identified in human cells; these forms have been designated hSRP1
(51), Rch1 (10), or
K2 (36) and hSRP1 (51), NPI-1 (38), or
K1 (36), and they share approximately 45 to 50% sequence
homology. The human karyopherin
has sequence homology similar to
that of the yeast karyopherin
(9, 38, 51). In addition
to karyopherins, nuclear translocation involves several other small
proteins such as the GTPase Ran/TC4 (8, 31-33) and
p10/NTF2 (39), as well as the nuclear pore proteins, nucleoporins (for a review, see reference 25).
The HIV-1 matrix protein (MA) contains one defined
(K26KKYK) and one putative (K110SKKK) NLS and
represents a major karyophilic structure within the PIC (5, 7, 16,
50). Synthetic peptides encompassing either of the two MA NLSs
bound to both hSRP1
(K2) and hSRP1 (K1) present in B-cell and T-cell
lysates (36). Mutations in the KKKYK NLS of MA, alone or in
combination with the deletion of Vpr, reduced the levels of nuclear
importation of the PIC and inhibited infection of primary macrophage
cultures (24, 50), as well as growth-arrested T cells
(6) and CD4+-HeLa cell cultures (13).
Amino acid substitutions within the KKKYK NLS also reduced the level of
binding of the PIC to yeast karyopherin
in vitro (12),
thus providing a link between the binding of PIC to karyopherin
,
nuclear import, and viral replication in nondividing cells.
In this study, we explored the role of active, receptor-mediated
nuclear importation in the infection of peripheral blood mononuclear
cell (PBMC) cultures using the arylene bis (methyl ketone) compound
CNI-H0294. This compound interacts primarily with the HIV-1 PIC by
forming Schiff-base adducts with lysine residues in the MA NLS
(12). We have previously shown that CNI-H0294 interferes
with the association of the PIC with the yeast karyopherin
(41) and effectively inhibits infection of primary
macrophage cultures with the macrophage-tropic isolate
HIVADA (50% inhibitory concentration [IC50], = 10 to 50 nM) (12). We now demonstrate that CNI-H0294
blocks the interaction between HIV-1 PIC and human karyopherin
and
reduces the level of nuclear importation of nascent HIV-1 cDNA in
activated T lymphocytes, resulting in substantial inhibition of viral
replication in both acute and chronic infection. These results provide
evidence for the critical role of nuclear importation in HIV-1
infection of primary T lymphocytes.
 |
MATERIALS AND METHODS |
HIV-1 strains.
The primary isolate HIV-1M1 was
described previously (26). HIV-1LAI is a T-cell
line-adapted virus isolate.
Cells.
PBMCs were collected from either seronegative or
seropositive individuals and were depleted of CD8+ T cells
by negative selection with a CD8-specific monoclonal antibody (MAb) and
rabbit complement as described previously (47).
Production of hSRP1
fusion protein.
The cDNA for hSRP1
was amplified by PCR from a phytohemagglutinin-activated human T-cell
cDNA library. The product was inserted into the pCDM8 expression vector
3' to the coding sequence for the CD5 signal peptide and 5' to the
sequence coding for the human Fc portion of immunoglobulin G1
(hinge-CH2-CH3). The hSRP1
-immunoglobulin fusion protein was derived
from COS cell lysates (lysis buffer, 0.1% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol in
phosphate-buffered saline [PBS]) following transient transfection
with the new construct. The glutathione-S-transferase hSRP1
(gst-hSRP1
) was derived from Escherichia coli
DH5
(Gibco-BRL, Grand Island, N.Y.) transformed with a construct
containing the hSRP1
gene inserted into the
BamHI-EcoRI sites of pGEX-2T. The fusion protein
was purified from disrupted bacteria by a one-step purification with a
glutathione column, followed by elution with 10 mM reduced glutathione
in PBS and subsequent dialysis against PBS.
Analysis of PIC-hSRP1
interaction.
Jurkat cells were
incubated with HIV-1LAI (200 ng of p24/106
cells) for 1 h, and then the cells were washed free of the virus inoculum and were allowed to incubate for an additional 3 h. The cells were lysed in ice-cold hypotonic buffer (10 mM Tris [pH 7.5],
10 mM KCl, 0.5 mM MgCl2, 1 µg each of leupeptin and
aprotinin per ml, 1 mM phenylmethylsulfonyl fluoride, and 1 U of RNasin per µl when needed) with a Dounce homogenizer. After removal of the
nuclei by centrifugation, the cytoplasmic fractions containing PICs
were adjusted to 150 mM NaCl and were then incubated with increasing
concentrations of compounds (0, 0.1, 1, and 10 µM) for 2 h prior
to the addition of the gst-hSRP1
fusion protein immobilized on
glutathione-coated beads. The beads were then assayed for the presence
of HIV-1-specific DNA by a standard PCR method as described previously
(47). Briefly, isolated cDNA was suspended in 10× PCR
buffer (200 mM Tris-HCl [pH 8.4], 500 mM KCl, 1.5 mM MgCl2), 250 mM 5'-oligonucleotide primer, and 2.5 U of
Taq polymerase (Boehringer Mannheim, Indianapolis, Ind.) for
a final reaction volume of 100 µl, and then the reaction was cycled
at 95°C for 0.5 min, 60°C for 1 min, and 72°C, for 1 min for 30 cycles. The amplified DNA products were transferred to a nylon membrane
and were hybridized to a [
-32P]ATP-labeled
gag-specific oligonucleotide probe as described previously
(22).
Analysis of HIV-1 nuclear import.
CD8+
T-cell-depleted PBMCs from a seronegative individual were activated for
1 h with an anti-CD3 MAb (MAb G19-4; 1 µg/ml) (11, 26, 34,
46, 47) in the presence of various concentrations of CNI-H0294
(0, 1, and 10 µM) and were then infected with the primary isolate,
HIV-1M1, (20 ng of p24/106 cells; six
replicates/treatment condition). In a similar experiment, Jurkat cells
were preincubated with CNI-H0294 (0 and 10 µM) for 1 h and were
then infected with HIV-1LAI (50 ng of p24/106
cells; six replicates/treatment condition). After a 1-h adsorption period, the virus inocula were washed out and the culture media were
supplemented with the appropriate concentrations of CNI-H0294. The
infections were allowed to proceed for either 40 h (PBMC cultures) or 20 h (Jurkat cells cultures), which allows a single replication cycle. The cells from the replicates were then pooled and lysed as
described previously (47), and the cell lysates were
evaluated for the presence of two long terminal repeat (2-LTR) circles
as described elsewhere (5); 2-LTR circles were used as
indicators of successful nuclear import (5, 12, 24, 50).
Cell lysates were also evaluated for the presence of HIV-1
gag sequences and
-globin sequences by PCR
(47); these data were used as indicators of virus entry,
reverse transcription, and input DNA levels in the PCR mixtures.
Analysis of HIV-1 replication.
CD8+
T-cell-depleted cultures of PBMCs from a seronegative individual were
activated with an anti-CD3 MAb (1 µg/ml) in the presence of various
concentrations of CNI-H0294 (0, 1, and 10 µM; six
replicates/treatment condition) for 2 h and then infected with
HIV-1M1 (20 ng of p24/106 cells). After a 1-h
adsorption period, the virus was washed away and the cultures were
supplemented with an anti-CD3 MAb (1 µg/ml) and the appropriate
concentration of CNI-H0294. Virus release was determined 6 days after
infection by measuring p24 levels in the culture supernatants by a
p24-specific enzyme-linked immunosorbent assay (34). In
parallel, cells were evaluated for viral DNA content by measuring the
levels of gag sequences by PCR techniques (47).
DNA levels were quantified by densitometric analysis of phosphor
screens with a Phosphorimager (Molecular Dynamics Inc., Sunnyvale,
Calif.).
-Globin sequences were evaluated as an indicator of input
DNA levels in the PCRs.
To determine the effects of CNI-H0294 on virus replication in
endogenously infected PBMC cultures, PBMCs were collected from seropositive individuals, depleted of CD8+ T cells, and
activated with an anti-CD3 MAb (1 µg/ml) in the presence of CNI-H0294
(six replicates/treatment condition). Virus production and virus load
were evaluated as described above.
Cell activation was measured by evaluating the incorporation of
[
3H]thymidine as described previously (
47).
 |
RESULTS |
CNI-H0294 inhibits binding of the HIV-1 PIC to human karyopherin
.
Since CNI-H0294 was previously shown to inhibit the
interaction of the HIV-1 PIC with the yeast karyopherin
(41), we tested the activity on binding of the HIV-1 PIC to
human karyopherin
. Jurkat cells were infected with
HIV-1LAI and lysed, and the postnuclear cytosolic fractions
containing the PIC were incubated with increasing concentrations of
CNI-H0294 for 2 h prior to binding to gst-hSRP1
fusion protein.
The gst-hSRP1
-PIC complexes were sedimented with glutathione-coated
Sepharose beads, and the presence of viral cDNA in the sedimented
fractions was evaluated by PCR. As indicated in Fig.
1, CNI-H0294 treatment reduced the levels of HIV-1 gag sequences that sedimented with gst-hSRP1
in
a dose-dependent fashion, suggesting that binding of the HIV-1 PIC to
the human karyopherin
was specifically blocked.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Binding of the HIV-1 preintegration complex to human
karyopherin . Jurkat cells were infected with HIV-1LAI
(200 ng of p24/106 cells). After a 20-h infection period
the cells were solubilized and the cell lysates were preincubated with
increasing concentrations of CNI-H0294, as indicated, prior to the
addition of gst-hSRP1 . The PIC-gst-hSRP1 complexes were
sedimented with glutathione-coated beads. The levels of HIV-1 DNA in
the sedimented fractions were evaluated by PCR.
|
|
CNI-H0294 inhibits nuclear importation of HIV-1 PIC in T
cells.
Since CNI-H0294 blocks the binding of the viral PIC to
human karyopherin
in vitro (Fig. 1), we wanted to determine if this inhibition had a measurable effect on nuclear importation during acute
infection of T cells. This question was addressed by assaying for the
presence of 2-LTR circles, a specific nuclear form of the HIV-1 genome
(5, 6), in cell lysates from infected cells. PBMCs from a
seronegative donor were depleted of CD8+ T cells and were
activated with a soluble anti-CD3 MAb in the presence of various
concentrations of CNI-H0294 (as indicated in the figure legends).
Activated cells were incubated with a primary isolate,
HIV-1M1 (47), for 1 h, and then the virus
inoculum was washed out and the cultures were supplemented with an
anti-CD3 MAb and the appropriate concentrations of CNI-H0294. After
40 h, the cells were lysed and the presence of 2-LTR circles was evaluated by PCR analysis with specific primers that span the LTR
junction. Figure 2a (autoradiograph)
shows that CNI-H0294 inhibited the formation of 2-LTR circles in a
dose-dependent fashion. The bar graph in Fig. 2a represents
densitometric quantitation of the various radiolabeled bands. This
effect was not unique for primary cells or primary isolates of HIV-1,
since CNI-H0294 also inhibited 2-LTR circle formation in Jurkat cells
acutely infected with HIV-1LAI (Fig. 2b). As for the PBMC
cultures, the Jurkat cells were infected for a short time (20 h), which
allows limited virus life cycles. The presence of equivalent levels of total viral DNA, as measured by the amount of gag sequences
in the Jurkat cell lysates (Fig. 2b), suggested that CNI-H0294
specifically altered nuclear importation but not virus entry or reverse
transcription. In support of the in vitro binding results (Fig. 1),
this reduced nuclear importation suggests that the association of the
incoming PIC with endogenous karyopherin
is essential for nuclear
localization of the HIV-1 genome in activated primary T lymphocytes and
dividing T cells from a T-cell line.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
CNI-H0294 inhibits 2-LTR circle formation in infected
cells. Anti-CD3 MAb-activated PBMC cultures (a) or Jurkat cell cultures
(b) were preincubated with CNI-H0294 and were infected with either
HIV-1M1 (20 ng of p24/106 cells) for 40 h
(a) or HIV-1LAI (50 ng of p24/106 cells) for
20 h (b) in the presence of the compound. The presence of 2-LTR
circle forms of the HIV-1 DNA was a measure of nuclear translocation,
while PCR analysis of gag sequences was used as a measure of
the overall HIV-1 DNA content, reflecting viral entry into the cells
and reverse transcription.
|
|
CNI-H0294 inhibits virus replication in activated PBMCs acutely
infected with a primary HIV-1 isolate.
To determine if inhibition
of the PIC-karyopherin
interaction and nuclear importation
influence HIV-1 replication in T cells, cultures of CD8
PBMCs from a seronegative donor were activated with an anti-CD3 MAb in
the presence of various concentrations of CNI-H0294 for 2 h and
were then acutely infected with HIV-1M1. The virus was allowed to adsorb for 1 h and was then washed out, and the
cultures were again supplemented with an anti-CD3 MAb and the
appropriate concentrations of CNI-H0294. Virus production and virus
load were determined 6 to 7 days after infection, while cell
proliferation was evaluated on day 4 after infection (see Materials and
Methods). The data indicated that CNI-H0294 substantially reduced the
level of virus infection in these cultures, as demonstrated by the
reduction in the p24 levels in the supernatants of treated cultures, as well as by the reduction of the viral DNA content in cell lysates (Fig.
3a, histogram and inset autoradiograph,
respectively). Whereas CNI-H0294 effectively reduced the level of virus
replication (IC50,
1 µM), cell proliferation, as
measured by the level of [3H]thymidine incorporation, was
much less affected (IC50, 10 µM) (Fig. 3b). These results
indicate that inhibition of the nuclear importation of the HIV-1 PIC
(Fig. 2a) correlates with a reduced levels of infection of activated T
cells.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
CNI-H0294 inhibits de novo infection of activated PBMCs.
PBMCs from a seronegative individual were activated with an anti-CD3
MAb in the presence of increasing concentrations of CNI-H0294, as
indicated, and were then infected with HIV-1M1 (20 ng of
p24/106 cells). (a) Virus production was evaluated on day 6 after activation by a p24-specific enzyme-linked immunosorbent assay;
the virus DNA content in pooled cell lysates was evaluated by PCR
(inset autoradiograph). (b) Cell proliferation was evaluated on day 4 after activation by measuring the level of incorporation of
[3H]thymidine.
|
|
CNI-H0294 inhibits virus replication in activated PBMCs from
seropositive individuals.
To determine if nuclear importation
plays a similar role in virus replication in the background of a
preexisting infection, we used freshly isolated PBMCs from
HIV-1-infected individuals. Infected individuals have integrated
provirus in their CD4+ T cells, and this provirus can be
induced in vitro by specific activation of the PBMCs with an anti-CD3
MAb (11, 34, 46, 47). The number of infected cells and the
levels of expression of the endogenous virus in the PBMCs are usually
low, so the measured virus output in these cultures is primarily a
result of amplification by virus spread to new targets (11, 34,
46, 47). Cultures of CD8
PBMCs from two
seropositive individuals (cultures Z78 and Z44), who we had previously
shown were responsive to anti-CD3 MAb-induced virus replication
(46), were activated in the presence of increasing concentrations of CNI-H0294. Virus production (Z78 and Z44
cultures) and virus load (Z78 cultures) were measured as described in
Materials and Methods. Figure 4a (inset
autoradiograph) indicates that the level of viral DNA in the Z78
cultures treated with CNI-H0294 was substantially lower (by more than
95% at 5 µM) than that in the untreated control cultures, suggesting
that the compound effectively reduced virus spread in the activated
PBMC cultures. Consistent with the observed reduction in the virus
load, CNI-H0294 also reduced the level of virus production, as measured
by the levels of HIV-1 p24 in the supernatants of treated versus
untreated cultures (Fig. 4a, histogram). As with the seronegative PBMCs
acutely infected with HIV-1 (Fig. 3), the proliferation of endogenously
infected PBMCs was only moderately affected by CNI-H0294 (for Z78
cultures, IC50 = 5 µM; for Z44 cultures, IC50 > 10 µM) (Fig. 4b, and d, respectively) compared to the effect of
CNI-H0294 on virus replication (IC50, <0.1 µM for both
donor cultures) (Fig. 4a and c, respectively). Moreover, CNI-H0294 was
not toxic to either primary cells or T-cell lines at the highest
concentration tested, as determined by exclusion of trypan blue (data
not shown). These results indicate that CNI-H0294 can effectively
inhibit virus replication in freshly isolated PBMCs from HIV-1-infected
individuals without significantly altering cell metabolism.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
CNI-H0294 limits virus replication in cultures of
activated PBMCs from seropositive individuals. PBMCs collected from two
seropositive individuals (PBMC culture Z78 [a and b]; PBMC culture
Z44 [c and d]) were activated with anti-CD3 MAb in the presence of
increasing concentrations of CNI-H0294 (as indicated). (a and c) Virus
production was evaluated on day 6 after activation as described in the
legend to Fig. 3. Viral DNA content (a, inset autoradiograph) in pooled
cell lysates was evaluated by PCR. (b and d) Cell proliferation was
evaluated on day 4 after activation.
|
|
 |
DISCUSSION |
Inhibitors of nuclear importation, such as high concentrations of
prototypic NLS peptides (22) which bind to karyopherin
or chemical entities such as CNI-H0294 that associate with NLS motifs
on the HIV-1 MA (12, 41), reduce the level of HIV-1 infection of growth-arrested T cells (22) and primary
macrophage cultures (12).
In this study we explored the role of nuclear importation in HIV-1
infection of activated T cells by using the compound CNI-H0294. Given
that the nuclear importation machinery is extremely well conserved in
different cell types, it is reasonable to assume that the mechanisms of
action of CNI-H0294 are similar in T cells and macrophages. Therefore,
this compound provides us with an opportunity to investigate the
nuclear importation of HIV-1 in the context of primary viral isolates
and primary cells from HIV-infected persons, something not possible by
other methods. We now show that CNI-H0294 inhibited the association of
HIV-1 PIC with human karyopherin
and that this association was
necessary for infection of activated PBMCs. Inhibition of nuclear
importation by CNI-H0294 was achievable in activated PBMCs acutely
infected in vitro with a primary isolate of HIV-1, as well as in Jurkat
cells infected with a laboratory isolate of the virus. Furthermore,
CNI-H0294 effectively inhibited virus replication following infection
of PBMCs with a large virus inoculum (Fig. 2 and 3). Activated PBMCs were less sensitive to the effects of CNI-H0294 on a molar basis than
primary macrophage cultures (100 versus 10 nM, respectively) (Fig. 3)
(12). This difference may be due in part to lower level of
uptake of the compound by activated T cells compared to that by
macrophages (4).
Similar to infection in vivo, the HIV-1 load in vitro is maintained
largely by recruitment of newly infected cells (11, 34, 46,
47). Thus, compounds that slow the rate of viral infection, as
CNI-H0294 does in T cells and macrophages, would be expected to reduce
the viral load significantly. This notion is supported by our
observations of a significant reduction of viral load by CNI-H0294 in
freshly isolated PBMCs from seropositive individuals (Fig. 4a and c).
The HIV-1 DNA detected in the treated cultures (Fig. 4a) is derived
primarily from integrated provirus in proliferating infected cells not
susceptible to the effects of the compound and from PIC-associated cDNA
sequestered by CNI-H0294 in the cytoplasm of newly infected cells. The
data presented for the PBMCs in the Z78 culture (Fig. 4a), which
exhibit relatively high levels of virus replication (approximately 1 µg of p24/ml of culture supernatant), and the PBMCs in the Z44
culture (Fig. 4c), which replicate virus to a lesser degree in response
to anti-CD3 activation, confirms the effectiveness of CNI-H0294 in the
presence of an existing virus infection. In addition, these results
indicate that the inhibitory effect of CNI-H0294 is not restricted to
any particular HIV-1 strain since cells from HIV-infected individuals harbor an uncloned mixture of virus quasispecies. Our results therefore
suggest that HIV-1 uses active nuclear importation during infection of
activated T cells.
The [3H]thymidine incorporation data presented in Fig. 4b
and d predict a therapeutic index for CNI-H0294 in HIV-1-infected donor
PBMCs of between
50 (Z78 culture) and
100 (Z44 culture). This
represents an underestimate since cell toxicity analysis by trypan blue
exclusion in PBMC cultures, release of lactate dehydrogenase from
primary macrophages cultures, or
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide metabolism
in immortalized cell lines treated with the drug showed an average
cytotoxic concentration equivalent to >200 µM (data not shown),
which significantly increases the therapeutic index. Furthermore,
CNI-H0294 was well tolerated by mice when it was administered as single
high-dose intraperitoneal injection or by daily subchronic (28 days)
intraperitoneal administration. For example, the 50% lethal dose for
the drug in mice was determined to be equivalent to 560 mg/kg
(3).
We and others have previously shown that virus replication in PBMC
cultures was dependent on cell activation (11, 34, 46, 47).
However, no consistent correlation between the magnitude of cell
proliferation and virus infection had been observed (11, 34, 46,
47). In fact, nonmitogenic stimulation was shown to induce de
novo transcription of the HIV-1 message (21, 52), as well as
virus production and amplification in PBMCs from seropositive individuals (2). Moreover, it has been shown that activated T cells arrested in the G1-S (5) or
G2 (45) phase of the cell cycle could be
infected with HIV-1, while G0-phase T cells were refractory
to productive infection (49, 53). These results suggest that
T-cell activation is both necessary and sufficient for productive
infection with HIV-1. Cell cycle analysis of freshly isolated PBMCs
from HIV-1-infected individuals indicated that CD4+ T cells
are either quiescent or resident in the early cell cycle phases, phases
G1 and S (48). In our experimental system,
freshly isolated PBMCs would be synchronously activated by an anti-CD3 MAb and would require up to 4 days of culture before entering mitosis.
Thus, the effects of CNI-H0294 on infection of activated PBMCs are most
likely exerted during cell cycle phases that precede mitosis
(G1-S and G2 phases) and which represent the
bulk of the cell cycle time. Given the defined mechanism of action of
CNI-H0294, it would be predicted that rapidly dividing cells in vitro,
such as PBMCs following mitogen stimulation (e.g., stimulation with phytohemagglutinin and interleukin 2), or immortalized T-cell lines
would be less sensitive to the antiviral effect of the drug. This is
consistent with our observation of the greatly reduced activity of
CNI-H0294 in infected MT-4 and CEM cultures. However, given that in
vivo the major proportion of T cells are quiescent, that T-cell
activation is tightly regulated, and that cell division requires long
periods of time (22 weeks for memory T cells) (30), CNI-H0294 and related compounds should significantly limit virus spread
and the number of infection cycles and thus effectively reduce the
viral load in vivo.
The mechanism of action of CNI-H0294 may include inhibition of other
HIV-1 NLSs, in addition to the major MA NLS (K26KKYK)
(41). Recently published reports (14, 15) suggest that this MA NLS is not the only karyophilic determinant in the HIV-1
PIC. In fact, additional NLS motifs have been identified in the C
terminus of MA (K110SKKK) (23, 36) and in
integrase (15). It is feasible to speculate that CNI-H0294
can form Schiff-base adducts with these lysine-rich NLSs, similar to
the formation of such adducts with the N-terminal MA NLS, thus
effectively inactivating all identified NLSs in the HIV-1 PIC. The Vpr
protein also seems to play a role in HIV-1 nuclear import
(24). However, Vpr, which lacks a classical NLS, binds to
karyopherin
in an NLS-independent manner (16, 40) and
appears to increase the affinity of karyopherin
for NLS-containing
proteins (40). Therefore, the karyophilic properties of Vpr
rely on the presence of other NLSs within the PIC. Under such a
scenario, even a Vpr-positive PIC would be left deficient in nuclear
import when the NLSs are inactivated. This is exactly the result
observed with CNI-H0294 (12; this study).
In conclusion, our study indicates that active nuclear importation
plays an important role in the infection of activated T cells and
supports the introduction of inhibitors of nuclear importation, such as
CNI-H0294, as novel therapeutic agents for intervention against HIV-1
infection.
 |
ACKNOWLEDGMENTS |
We thank Kathleen Critchett and Doug Tritschler for technical
assistance.
M.I.B. is supported in part by NIH grants RO1AI40386 and RO1AI33776.
This work was supported by Bristol-Myers Squibb Pharmaceutical Research
Institute.
 |
FOOTNOTES |
*
Corresponding author. Present address: Cytokine
Networks Inc., 101 Elliot Ave. West, Suite 428, Seattle, WA 98119. Phone: (206) 283-0236. Fax: (206) 270-3300. E-mail:
okhaffar{at}wolfenet.com.
 |
REFERENCES |
| 1.
|
Adam, S. A., and L. Gerace.
1991.
Cytosolic proteins that specifically bind nuclear location signals are receptors for nuclear import.
Cell
66:837-847[Medline].
|
| 2.
|
Åsjö, B.,
D. Cefai,
P. Debré,
Y. Dudoit, and B. Autran.
1993.
A novel mode of human immunodeficiency virus type 1 (HIV-1) activation: ligation of CD28, activates the long terminal repeat.
J. Virol.
67:4395-4398[Abstract/Free Full Text].
|
| 3.
| Bukrinsky, M. I. Unpublished data.
|
| 4.
| Bukrinsky, M. I. Data not shown.
|
| 5.
|
Bukrinsky, M. I.,
S. Haggerty,
M. P. Dempsey,
N. Sharova,
A. Adzhubei,
L. Spitz,
P. Lewis,
D. Goldfarb,
M. Emerman, and M. Stevenson.
1993.
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.
Nature
365:666-669[Medline].
|
| 6.
|
Bukrinsky, M. I.,
N. Sharova,
M. P. Dempsey,
T. L. Stanwick,
A. G. Bukrinskaya,
S. Haggerty, and M. Stevenson.
1992.
Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.
Proc. Natl. Acad. Sci. USA
89:6580-6584[Abstract/Free Full Text].
|
| 7.
|
Bukrinsky, M. I.,
N. Sharova,
T. L. McDonald,
T. Pushkarskaya,
W. G. Tarpley, and M. Stevenson.
1993.
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.
Proc. Natl. Acad. Sci. USA
90:6125-6129[Abstract/Free Full Text].
|
| 8.
|
Corbett, A. H.,
D. M. Koepp,
G. Schlenstedt,
M. S. Lee,
A. K. Hopper, and P. A. Silver.
1995.
Rna 1p, a Ran/TC4 GTPase activating protein, is required for nuclear import.
J. Cell Biol.
130:1017-1026[Abstract/Free Full Text].
|
| 9.
|
Cortes, P.,
Z.-S. Ye, and D. Baltimore.
1994.
RAG-1 interacts with the repeated amino acid motif of the human homologue of the yeast protein SRP1.
Proc. Natl. Acad. Sci. USA
91:7633-7637[Abstract/Free Full Text].
|
| 10.
|
Cuomo, C. A.,
S. A. Kirch,
J. Gyuris,
R. Brent, and M. A. Ottinger.
1994.
Rch1, a protein that specifically interacts with the RAG-1 recombination-activating protein.
Proc. Natl. Acad. Sci. USA
91:6156-6160[Abstract/Free Full Text].
|
| 11.
|
Diegel, M. L.,
P. A. Moran,
L. K. Gilliland,
N. K. Damle,
M. S. Hayden,
J. M. Zarling, and J. A. Ledbetter.
1993.
Regulation of HIV-1 production by blood mononuclear cells from HIV-infected donors: HIV-1 production depends on T cell-monocyte interaction.
AIDS Res. Hum. Retroviruses
9:465-473[Medline].
|
| 12.
|
Dubrovsky, L.,
P. Ulrich,
G. J. Nuovo,
K. R. Manogue,
A. Cerami, and M. Bukrinsky.
1995.
Nuclear localization signal of HIV-1 as a novel target for therapeutic intervention.
Mol. Med.
1:217-230[Medline].
|
| 13.
|
Emerman, M.,
M. Bukrinsky, and M. Stevenson.
1994.
HIV-1 infection of nondividing cells.
Nature (London)
369:107-108[Medline].
|
| 14.
|
Fouchier, R. A. M.,
B. E. Meyer,
J. H. M. Simon,
U. Fischer, and M. H. Malim.
1997.
HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for gag processing but not for post-entry nuclear import.
EMBO J.
16:4531-4539[Medline].
|
| 15.
|
Gallay, P.,
T. Hope,
D. Chin, and D. Trono.
1997.
HIV-1 infection of non-dividing cells through the recognition of integrase by the importin/karyopherin pathway.
Proc. Natl. Acad. Sci. USA
94:9825-9830[Abstract/Free Full Text].
|
| 16.
|
Gallay, P.,
V. Stitt,
C. Mundy,
M. Oettinger, and D. Trono.
1996.
Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import.
J. Virol.
70:1027-1032[Abstract].
|
| 17.
|
Gartner, S.,
P. Markovits,
D. M. Markovitz,
M. H. Kaplan,
R. C. Gallo, and M. Popovic.
1986.
The role of mononuclear phagocytes in HTLV-III/LAV infection.
Science
233:215-219[Abstract/Free Full Text].
|
| 18.
|
Gendelman, H. E.,
O. Narayan,
S. Kennedy-Stoskopf,
P. G. E. Kennedy,
Z. Ghotbi,
J. E. Clements,
J. Stanley, and G. Pezeshkpour.
1986.
Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages.
J. Virol.
58:67-74[Abstract/Free Full Text].
|
| 19.
|
Görlich, D., and J. W. Mattaj.
1996.
Nucleocytoplasmic transport.
Science
271:1513-1518[Abstract].
|
| 20.
|
Görlich, D.,
F. Vogel,
A. D. Mills,
E. Hartmann, and R. A. Laskey.
1995.
Distinct functions for the two importin subunits in nuclear protein import.
Nature (London)
377:246-248[Medline].
|
| 21.
|
Gruters, R. A.,
S. A. Otto,
B. J. M. Al,
A. J. Verhoeven,
R. A. W. Van Lier, and F. Miedema.
1991.
Non-mitogenic T cell activation signals are sufficient for induction of human immunodeficiency virus transcription.
Eur. J. Immunol.
21:167-172[Medline].
|
| 22.
|
Gulizia, J.,
M. P. Dempsey,
N. Sharova,
M. I. Bukrinsky,
L. Spitz,
D. Goldfarb, and M. Stevenson.
1994.
Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal.
J. Virol.
68:2021-2025[Abstract/Free Full Text].
|
| 23.
| Haffar, O. K., and M. I. Bukrinsky.
Unpublished data.
|
| 24.
|
Heizinger, N. K.,
M. I. Bukrinsky,
S. A. Haggerty,
A. M. Ragland,
V. Kewalramani,
M.-A. Lee,
H. E. Gendelman,
L. Ratner,
M. Stevenson, and M. Emerman.
1992.
The Vpr protein of HIV-1 influences nuclear localization of viral nucleic acids in non-dividing host cells.
Proc. Natl. Acad. Sci. USA
91:7311-7315[Abstract/Free Full Text].
|
| 25.
|
Hurt, E. C.
1996.
Importins/karyopherins meet nucleoporins.
Cell
84:509-515[Medline].
|
| 26.
|
Kanner, S. B., and O. K. Haffar.
1995.
HIV-1 down-regulates CD4 costimulation of TCR/CD3-directed tyrosine phosphorylation through CD4/p56lck dissociation.
J. Immunol.
154:2996-3005[Abstract].
|
| 27.
|
Langhoff, E.,
E. F. Terwilliger,
H. J. Bos,
K. H. Kalland,
M. C. Poznasky,
O. M. L. Bacon, and W. A. Haseltine.
1991.
Replication of human immunodeficiency virus type in primary dendritic cell cultures.
Proc. Natl. Acad. Sci. USA
88:7998-8002[Abstract/Free Full Text].
|
| 28.
|
Lewis, P.,
M. Hensel, and M. Emerman.
1992.
Human immunodeficiency virus infection of cells arrested in the cell cycle.
EMBO J.
11:3053-3058[Medline].
|
| 29.
|
Lewis, P. F., and M. Emerman.
1994.
Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.
J. Virol.
68:510-516[Abstract/Free Full Text].
|
| 30.
|
McLean, A. R., and C. A. Michie.
1995.
In vivo estimates of division and death rates of human T lymphocytes.
Proc. Natl. Acad. Sci. USA
92:3707-3711[Abstract/Free Full Text].
|
| 31.
|
Melchior, F.,
T. Guan,
N. Yokoyama,
T. Nishimoto, and L. Gerace.
1995.
GTP hydrolysis by Ran occurs at the nuclear pore complex in an early step of protein import.
J. Cell Biol.
131:571-581[Abstract/Free Full Text].
|
| 32.
|
Moore, M. S., and G. Blobel.
1993.
The GTP-binding protein Ran/TC4 is required for protein import into the nucleus.
Nature
365:661-663[Medline].
|
| 33.
|
Moore, M. S., and G. Blobel.
1994.
Purification of Ran-interacting protein that is required for protein import into the nucleus.
Proc. Natl. Acad. Sci. USA
91:10212-10216[Abstract/Free Full Text].
|
| 34.
|
Moran, P. A.,
M. L. Diegel,
J. C. Sias,
J. A. Ledbetter, and J. M. Zarling.
1993.
Regulation of HIV-1 production by blood mononuclear cells from HIV-infected donors. I. Lack of correlation between HIV-1 production and cell activation.
AIDS Res. Hum. Retroviruses
9:455-464[Medline].
|
| 35.
|
Moroianu, J.,
G. Blobel, and A. Radu.
1995.
Previously identified protein of uncertain function is karyopherin and together with karyopherin docks import substrate at the nuclear pore complex.
Proc. Natl. Acad. Sci. USA
92:2008-2011[Abstract/Free Full Text].
|
| 36.
|
Nadler, S. G.,
D. Tritschler,
O. K. Haffar,
J. Blake,
A. G. Bruce, and J. S. Cleaveland.
1997.
Differential expression and sequence-specific interaction of karyopherin with nuclear localization sequences.
J. Biol. Chem.
272:4310-4315[Abstract/Free Full Text].
|
| 37.
|
Nigg, E. A.
1997.
Nucleocytoplasmic transport: signals, mechanisms, and regulation.
Nature
386:779-787[Medline].
|
| 38.
|
O'Neill, R. E., and P. Palese.
1995.
NPI-1, the human homologue of SRP-1, interacts with influenza virus nucleoprotein.
Virology
206:116-125[Medline].
|
| 39.
|
Paschal, B. M., and L. Gerace.
1995.
Identification of NTF2, a cytosolic factor for nuclear protein import that interacts with nuclear pore complex protein p62.
J. Cell Biol.
129:925-937[Abstract/Free Full Text].
|
| 40.
|
Popov, S.,
M. Rexach,
G. Zybarth,
N. Reiling,
M.-A. Lee,
L. Ratner,
C. M. Lane,
M. S. Moore,
G. Blobel, and M. Bukrinsky.
1998.
Viral protein R regulates nuclear import of the HIV-1 pre-integration complex.
EMBO J.
17:909-917[Medline].
|
| 41.
|
Popov, S.,
L. Dubrovsky,
M.-A. Lee,
S. Pennathur,
O. Haffar,
Y. Al-Abed,
P. Tonge,
P. Ulrich,
M. Rexach,
G. Blobel,
A. Cerami, and M. Bukrinsky.
1996.
Critical role of reverse transcriptase in the inhibitory mechanism of CNI-H0294 on HIV-1 nuclear translocation.
Proc. Natl. Acad. Sci. USA
93:11859-11864[Abstract/Free Full Text].
|
| 42.
|
Radu, A.,
G. Blobel, and M. S. Moore.
1995.
Identification of a protein complex that is required for nuclear protein import and mediates docking of import substrate to distinct nucleoporins.
Proc. Natl. Acad. Sci. USA
92:1769-1773[Abstract/Free Full Text].
|
| 43.
|
Ramazzotti, E.,
A. Marconi,
M. C. Re,
G. Girolomoni,
G. Cenacchi,
M. Vignoli,
G. Zambruno,
G. Furlini,
M. La Placa, and A. Giannetti.
1995.
In vitro infection of human epidermal Langerhans' cells with HIV-1.
Immunology
85:94-98[Medline].
|
| 44.
|
Roe, T. Y.,
T. C. Reynolds,
G. Yu, and P. O. Brown.
1993.
Integration of murine leukemia virus DNA depends on mitosis.
EMBO J.
12:2099-2108[Medline].
|
| 45.
|
Rogel, M. E.,
L. I. Wu, and M. Emerman.
1995.
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.
J. Virol.
69:882-888[Abstract].
|
| 46.
|
Smithgall, M. D.,
J. G. P. Wong,
K. E. Critchett, and O. K. Haffar.
1996.
IL-7 upregulates HIV-1 replication in naturally infected peripheral blood mononuclear cells.
J. Immunol.
156:2324-2330[Abstract].
|
| 47.
|
Smithgall, M. D.,
J. G. P. Wong,
P. S. Linsley, and O. K. Haffar.
1995.
Costimulation of CD4+ T cells via CD28 modulates human immunodeficiency virus type 1 infection and replication in vitro.
AIDS Res. Hum. Retroviruses
11:885-892[Medline].
|
| 48.
|
Spina, C. A.,
J. C. Guatelli, and D. D. Richman.
1995.
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.
J. Virol.
69:2977-2988[Abstract].
|
| 49.
|
Stevenson, M.,
T. L. Stanwick,
M. P. Dempsey, and C. A. Lamonica.
1990.
HIV-1 replication is controlled at the level of T cell activation and proviral integration.
EMBO J.
9:1551-1560[Medline].
|
| 50.
|
von Schwedler, U.,
R. S. Kornbluth, and D. Trono.
1994.
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.
Proc. Natl. Acad. Sci. USA
91:6992-6996[Abstract/Free Full Text].
|
| 51.
|
Weis, K.,
I. W. Mattaj, and A. I. Lamond.
1995.
Identification of hSRP1 as a functional receptor for nuclear localization sequences.
Science
268:1049-1053[Abstract/Free Full Text].
|
| 52.
|
Wong, J. G. P.,
M. D. Smithgall, and O. K. Haffar.
1997.
TCR-independent CD28-mediated gene expression in peripheral blood lymphocytes from donors chronically infected with HIV-1.
Immunology
90:281-285[Medline].
|
| 53.
|
Zack, J. A.,
S. J. Arrigo,
S. R. Weitsman,
A. S. Go,
A. Haislip, and I. S. Y. Chen.
1990.
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
Cell
61:213-222[Medline].
|
Antimicrobial Agents and Chemotherapy, May 1998, p. 1133-1138, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Haffar, O., Dubrovsky, L., Lowe, R., Berro, R., Kashanchi, F., Godden, J., Vanpouille, C., Bajorath, J., Bukrinsky, M.
(2005). Oxadiazols: a New Class of Rationally Designed Anti-Human Immunodeficiency Virus Compounds Targeting the Nuclear Localization Signal of the Viral Matrix Protein. J. Virol.
79: 13028-13036
[Abstract]
[Full Text]
-
Iordanskiy, S., Zhao, Y., DiMarzio, P., Agostini, I., Dubrovsky, L., Bukrinsky, M.
(2004). Heat-shock protein 70 exerts opposing effects on Vpr-dependent and Vpr-independent HIV-1 replication in macrophages. Blood
104: 1867-1872
[Abstract]
[Full Text]
-
Bahr, G. M., Darcissac, E. C. A., Casteran, N., Amiel, C., Cocude, C., Truong, M.-J., Dewulf, J., Capron, A., Mouton, Y.
(2001). Selective Regulation of Human Immunodeficiency Virus-Infected CD4+ Lymphocytes by a Synthetic Immunomodulator Leads to Potent Virus Suppression In Vitro and in hu-PBL-SCID Mice. J. Virol.
75: 6941-6952
[Abstract]
[Full Text]